Long-term topical cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryoadenitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 3, 2009, Pages 285-291

  Thomas, Padmaja B ^a   Samant, Deedar M ^a   Zhu, Zejin ^a   Selvam, Shivaram ^a,b   Stevenson, Douglas ^a   Wang, Yanru ^c   Song, Sang W ^a   Mircheff, Austin K ^a,c   Schechter, Joel E ^a,c   Yiu, Samuel C ^a,c   Trousdale, Melvin D ^a  

^a DOHENY EYE INSTITUTE   (United States)

^b University of Southern California ^*  (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ROSE BENGAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DACRYOADENITIS; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; DACRYOCYSTITIS; DRUG EFFICACY; DRY EYE; EXPERIMENTAL RABBIT; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; KERATOCONJUNCTIVITIS; LACRIMAL GLAND; LACRIMATION; LONG TERM CARE; NONHUMAN; PROTEIN EXPRESSION;

ADMINISTRATION, TOPICAL; ANIMALS; AUTOIMMUNE DISEASES; CYCLOSPORINE; DACRYOCYSTITIS; DRUG ADMINISTRATION SCHEDULE; DRY EYE SYNDROMES; FEMALE; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS; RABBITS; T-LYMPHOCYTES; TEARS;

EID: 66249137138     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0138     Document Type: Article

References (30)

1. Fox, R.I., and Kang, H.I. Pathogenesis of Sjogren's syndrome. Rheum. Dis. Clin. North Am. 18:517-538, 1992.
2. Lemp, M.A. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 21:221-232, 1995.
3. Sullivan, D.A., and Edwards, J.A. Androgen stimulation of lacrimal gland function in mouse models of Sjogren's syndrome. J. Steroid Biochem. Mol. Biol. 60:237-245, 1997.
4. Stevenson, D., Tauber, J., and Reis, B.L. Eff cacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967-974, 2000.
5. Sall, K., Stevenson, O.D., Mundorf, T.K., et al. Two multicenter, randomized studies of the eff cacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107:631-639, 2000.
6. Barabino, S., and Dana, M.R. Dry eye syndromes. Chem. Immunol. Allergy 92:176-184, 2007.
7. Zhu, Z., Stevenson, D., Schechter, J.E., et al. Lacrimal histopathology and ocular surface disease in a rabbit model of autoimmune dacryoadenitis. Cornea 22:25-32, 2003.
8. Niederkorn, J.Y., Stern, M.E., Pf ugfelder, S.C., et al. Desiccating stress induces T cell-mediated Sjogren's Syndrome-like lacrimal keratoconjunctivitis. J. Immunol. 176:3950-3957, 2006.
9. Pf ugfelder, S.C., Tseng, S.C., Sanabria, O., et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-f lm disorders known to cause ocular irritation. Cornea 17:38-56, 1998.
10. Pf ugfelder, S.C., Solomon, A., Dursun, D., et al. Dry eye and delayed tear clearance: "a call to arms." Adv. Exp. Med. Biol. 506:739-743, 2002.
11. Kaswan, R.L., Martin, C.L., and Chapman, W.L., Jr. Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs. Am. J. Vet. Res. 45:112-118, 1984.
12. Kaswan, R.L., Martin, C.L., and Dawe, D.L. Rheumatoid factor determination in 50 dogs with keratoconjunctivitis sicca. J. Am. Vet. Med. Assoc. 183:1073-1075, 1983.
13. Kaswan, R.L., Martin, C.L., and Dawe, D.L. Keratoconjunctivitis sicca: immunological evaluation of 62 canine cases. Am. J. Vet. Res. 46:376-383, 1985.
14. Pflugfelder, S.C. Anti-inf ammatory therapy of dry eye. Ocul. Surf. 1:31-36, 2003.
15. Baudouin, C., and Liang, H. Amplifying factors in ocular surface diseases: apoptosis. Ocul. Surf. 3:S194-S197, 2005.
16. Kaswan, R.L., Salisbury, M.A., and Ward, D.A. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch. Ophthalmol. 107:1210-1216, 1989.
17. Kunert, K.S., Tisdale, A.S., and Gipson, I.K. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch. Ophthalmol. 120:330-337, 2002.
18. Pf ugfelder, S.C., De Paiva, C.S., Villarreal, A.L., et al. Effects of sequential artif cial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 27:64-69, 2008.
19. Pf ugfelder, S.C. Antiinf ammatory therapy for dry eye.Am. J. Ophthalmol. 137:337-342, 2004.
20. Guo, Z., Song, D., Azzarolo, A.M., et al. Autologous lacrimallymphoid mixed-cell reactions induce dacryoadenitis in rabbits. Exp. Eye Res. 71:23-31, 2000.
21. Zhu, Z., Stevenson, D., Ritter, T., et al. Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea 21:210-214, 2002.
22. Trousdale, M.D., Zhu, Z., Stevenson, D., et al. Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J. Autoimmune Dis. 2:6, 2005.
23. Lemp, M.A. Management of dry eye disease. Am. J. Manag. Care 14:S88-S101, 2008.
24. Hyon, J.Y., Lee, Y.J., and Yun, P.Y. Management of ocular surface inf ammation in Sjogren's syndrome. Cornea 26:S13-S15, 2007.
25. Thomas, P.B., Zhu, Z., Selvam, S., et al. Autoimmune dacryoadenitis and keratoconjunctivitis induced in rabbits by subcutaneous injection of autologous lymphocytes activated ex vivo against lacrimal antigens. J. Autoimmun. 31:116-122, 2008.
26. Duncan, N., and Craddock, C. Optimizing the use of cyclosporin i n al logeneic st em cel l t ra n spla ntation. B one Marrow Tra n spla nt. 38:169-174, 2006.
27. Wang, Y., Ogawa, Y., Dogru, M., et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 41:293-302, 2008.
28. Lelli, G.J., Jr., Musch, D.C., Gupta, A., et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 25:635-638, 2006.
29. Pepose, J.S., Akata, R.F., Pf ugfelder, S.C., et al. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjogren's syndrome. Ophthalmology 97:1599-1605, 1990.
30. Oak, J.S., Deane, J.A., Kharas, M.G., et al. Sjogren's syndromelike disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc. Natl. Acad. Sci. USA. 103:16882-16887, 2006.